Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Wave Life Sciences, Inc. - Common Stock
(NQ:
WVE
)
3.220
-0.400 (-11.05%)
Delayed Quote
Updated: 4:00 PM EST, Nov 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Wave Life Sciences, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
WAVE Life Sciences Targets Genetic Liver Disease With WVE-008 RNA Editing Program
↗
November 04, 2026
WAVE Life Sciences (NASDAQ:WVE) used its 2026 Research Day to outline plans for WVE-008, an RNA-editing candidate being developed for liver disease associated with the PNPLA3 I148M genetic variant,...
Via
MarketBeat
Wave Life Sciences (WVE) Q3 2026 Earnings Call Transcript
↗
October 27, 2026
RNA medicine company advances obesity and lung disease programs with $431M cash runway.
Via
The Motley Fool
Topics
Earnings
WAVE Life Sciences Q3 Earnings Call Highlights
↗
October 27, 2026
WAVE Life Sciences (NASDAQ:WVE) reported higher third-quarter revenue and a wider net loss as it increased investment in clinical programs spanning obesity, alpha-1 antitrypsin deficiency and liver...
Via
MarketBeat
Topics
Earnings
Wave Life Sciences (NASDAQ:WVE) Plunges After Q2 Revenue Miss
↗
July 30, 2026
Via
Chartmill
Wave Life Sciences Reports Third Quarter 2026 Financial Results and Provides Business Update
October 27, 2026
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
WAVE Life Sciences Highlights Obesity Data, FDA-Aligned RNA Editing Path
↗
October 21, 2026
WAVE Life Sciences (NASDAQ:WVE) outlined progress across its obesity-focused siRNA program and RNA editing pipeline during a Chardan discussion, with President and CEO Paul Bolno emphasizing the...
Via
MarketBeat
Wave Life Sciences Third Quarter 2026 Financial Results Scheduled for October 27, 2026
October 20, 2026
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences to Host Virtual Research Day on Wednesday, November 4, 2026
October 19, 2026
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences to Present at Chardan’s 10th Annual Healthcare Conference
October 13, 2026
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences Announces FDA Feedback Supports Registrational Pathway for WVE-006 (RNA Editing) in AATD
October 01, 2026
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences Announces GSK’s Selection of siRNA program to Transition to GSK for Further Development
September 30, 2026
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences Initiates Phase 2a Combination Trial of WVE-007 (GalNAc-siRNA) with Tirzepatide for Obesity
September 23, 2026
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences Announces Appointment of Dr. Monika Vnuk as Chief Business Officer
September 22, 2026
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences to Present at Cantor 2026 Global Healthcare Conference
September 03, 2026
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences Announces Completion of Redomiciliation to Delaware
August 10, 2026
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences Announces Expected Completion Date for Redomiciliation to Delaware
August 05, 2026
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences to Present at Upcoming Investor Conferences
August 04, 2026
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences (WVE) Q2 2026 Earnings Call Transcript
↗
August 03, 2026
WVE-007 obesity candidate shows 16.5% visceral fat improvement in early trials.
Via
The Motley Fool
Topics
Earnings
Wave Life Sciences (WVE) Q2 2026 Earnings Call Transcript
↗
July 30, 2026
WVE-007 obesity candidate shows 16.5% visceral fat improvement in early trials.
Via
The Motley Fool
Topics
Earnings
WAVE Life Sciences Q2 Earnings Call Highlights
↗
July 30, 2026
WAVE Life Sciences (NASDAQ:WVE) reported a wider second-quarter loss as it increased investment in its obesity and RNA-editing programs, while outlining several clinical and regulatory milestones...
Via
MarketBeat
Topics
Earnings
Wave Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update
July 30, 2026
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences Second Quarter 2026 Financial Results Scheduled for July 30, 2026
July 23, 2026
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences Announces Singapore Court Hearing, to be held on July 14, 2026 to Approve Scheme of Arrangement for Redomiciliation
July 07, 2026
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences Announces Initiation of Phase 2a Portion of INLIGHT™ Trial of WVE-007 (INHBE GalNAc-siRNA) for Obesity and Cardiometabolic Diseases
June 24, 2026
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences to Present at Upcoming Investor Conferences
June 01, 2026
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
This $5.5 Million Exit Raises Questions After Wave Life Sciences' Rough First Quarter
↗
May 31, 2026
This clinical-stage biotech develops precision genetic medicines for neurological and hepatic disorders via its PRISM platform.
Via
The Motley Fool
Topics
Regulatory Compliance
Wave Life Sciences Announces Positive Update on RestorAATion-2 Trial: WVE-006 (GalNAc-RNA Editing) Achieves MZ-Like Phenotype Across Both Biweekly and Monthly Dosing
May 18, 2026
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences to Present at 2026 RBC Capital Markets Global Healthcare Conference
May 13, 2026
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave (WVE) Q1 2026 Earnings Call Transcript
↗
April 29, 2026
Wave (WVE) Q1 2026 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Wave (WVE) Q2 2025 Earnings Call Transcript
↗
April 28, 2026
Wave (WVE) Q2 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
